A. Adjei

V. Papadimitrakopoulou, A. Adjei, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Development and Reporting of Prediction Models: Guidance for Authors From Editors of Respiratory, Sleep, and Critical Care Journals

J. Wedzicha, J. Crapo, A. Sheikh, 2020, Critical care medicine.

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

Steven E Schild, Ping Yang, Ping Yang, 2008, Mayo Clinic proceedings.

Analysis of second primary lung cancers in the SEER database.

Mary E Reid, Paul C Tang, Terry Mashtare, 2010, The Journal of surgical research.

Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer - Current Concepts and Future Approaches.

S. Mandrekar, D. Wigle, A. Adjei, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial

H. Wakelee, D. Gandara, S. Ramalingam, 2017, The Lancet. Oncology.

Novel anticancer agents : strategies for discovery and clinical testing

J. Buolamwini, A. Adjei, 2006 .

Effective Incorporation of Biomarkers into Phase II Trials

Lisa M. McShane, Sally Hunsberger, L. McShane, 2009, Clinical Cancer Research.

Abstract 1: Mcl-1 downregulation plays a crucial role in the synergistic anticancer activities between PI-3 kinase inhibitors and histone deacetylase inhibitors in primary NSCLC tumorsin vitroandin vivo

Hao Zhang, Elizabeth A. Repasky, Grace K. Dy, 2011 .

A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

M. Sherman, A. Hezel, A. El-Khoueiry, 2015, Clinical Cancer Research.

Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.

Robert Schmieder, A. Adjei, K. Ziegelbauer, 2013, Neoplasia.

Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs

Shaji K. Kumar, S. Rajkumar, A. Adjei, 2010, Oncogene.

Novel Agents on the Horizon for Cancer Therapy

W. Ma, A. Adjei, Wen W. Ma, 2009, CA: a cancer journal for clinicians.

K-ras as a Target for Lung Cancer Therapy

A. Adjei, Alex A. Adjei, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer

Sumithra J. Mandrekar, J. Jett, S. Mandrekar, 2007, Clinical Cancer Research.

Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways

J. Sarkaria, L. Roberts, S. Kaufmann, 2006, Molecular Cancer Therapeutics.

Targeting multiple signal transduction pathways in lung cancer.

A. Adjei, Alex A Adjei, 2005, Clinical lung cancer.

Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing.

Jing Pan, Peng Cui, Haiming Xu, 2012, Carcinogenesis.

Early-stage lung cancer : immunotherapeutic standards S 71 EGFR-mutant disease : strategies against sensitizing and resistance-mediating mutations S 76 KRAS

A. Adjei, F. Marinis, 2021 .

Consensus Report of the 2015 Weinman International Conference on Mesothelioma

J. Peto, W. Mao, F. Hirsch, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma

J. Sloan, N. Foster, M. Aubry, 2008, Cancer.

Comparison of Potential Markers of Farnesyltransferase Inhibition 1

C. Erlichman, S. Kaufmann, P. Svingen, 2000 .

Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT)

E. D. de Vries, L. Seymour, J. Tabernero, 2020, Clinical Cancer Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials.

A. Mansfield, A. Adjei, J. Molina, 2018, The oncologist.

Pathophysiology and treatment of hot flashes.

T. Shanafelt, C. Loprinzi, A. Adjei, 2002, Mayo Clinic proceedings.

Novel targets for lung cancer therapy: part II.

A. Adjei, G. Dy, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer.

A. Adjei, 1999, British journal of clinical pharmacology.

Antibody‐Drug Conjugates for the Therapy of Thoracic Malignancies

A. Adjei, Hao Xie, 2019, Journal of Thoracic Oncology.

A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.

E. Perez, J. Ingle, J. Kugler, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies

D. Hodge, A. Adjei, Y. Lou, 2018, Journal of Immunotherapy for Cancer.

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib

Suzanne F. Jones, S. Novello, H. Burris, 2013, Investigational New Drugs.

When your favorite patient relapses: physician grief and well-being in the practice of oncology.

T. Shanafelt, A. Adjei, F. Meyskens, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiologic Considerations And Standardization Of Malignant Pleural Mesothelioma (MPM) Imaging Within Clinical Trials: Consensus Statement From The NCI Thoracic Malignancy Steering Committee - International Association For The Study Of Lung Cancer - Mesothelioma Applied Research Foundation Clinical T

S. Armato, E. Yorke, K. Rosenzweig, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors

S. Sanderson, C. Moser, L. Roberts, 2010, Liver international : official journal of the International Association for the Study of the Liver.

A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer

S. Mandrekar, A. Adjei, G. Dy, 2005, Cancer Chemotherapy and Pharmacology.

Angiogenesis inhibitors in lung cancer: a promise fulfilled.

A. Adjei, G. Dy, Alex A Adjei, 2006, Clinical lung cancer.

Novel small-molecule inhibitors of the vascular endothelial growth factor receptor.

A. Adjei, 2007, Clinical lung cancer.

Principles of chemotherapy

A. Adjei, G. Dy, 2006 .

A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

S. Larson, A. Scott, J. Ingle, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

myelogenous leukemia poor-risk and elderly patients with previously untreated acute A phase 2 study of the farnesyltransferase inhibitor tipifarnib in

P. Greenberg, J. Karp, S. Kaufmann, 2010 .

Sequencing bortezomib with chemotherapy and targeted agents.

A. Adjei, 2005, Clinical lung cancer.

A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer

S. Mandrekar, G. Wilding, S. Alberts, 2005, Clinical Cancer Research.

APhase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor , PS-341 ( Bortezomib , Velcade ) , in Patientswith Advanced Cancer

S. Alberts, H. Pitot, C. Erlichman, 2005 .

Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?

H. Choy, H. Wakelee, N. Saijo, 2008, Clinical lung cancer.

The value of combined‐modality therapy in elderly patients with stage III nonsmall cell lung cancer

J. Jett, S. Mandrekar, A. Adjei, 2007, Cancer.

The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

E. Yorke, K. Rosenzweig, V. Rusch, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Signal-Regulated Kinase and Raf Proteins Negative Feedback Pathways between Extracellular BRAF V 600 E Disrupts AZD 6244-Induced Abrogation of Updated

S. Thibodeau, Liang Wang, Paul D. Smith, 2008 .

Inhibitors of Raf kinase and MEK signaling

A. Adjei, N. Ramnath, 2007 .

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006

G. Gores, S. Kaufmann, X. Meng, 2005, Oncogene.

Lung Cancer Awareness Month-A Lot of Progress, But More Work Needs to Be Done.

A. Adjei, M. F. Henningfield, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

E-2. Inhibitors of MAP kinases

A. Adjei, 2003 .

Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group.

E. Perez, J. Jett, S. Hillman, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

When Y our F avorite P atient R elapses: P hysician G rief a nd Well-Being i n t he P ractice o f O ncology

T. Shanafelt, A. Adjei, F. Meyskens, 2003 .

Obstacles and opportunities in the clinical development of targeted therapeutics.

A. Adjei, G. Dy, 2005, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.

J. Sloan, M. Goetz, R. Goldberg, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors

J. Sloan, L. Denis, S. Alberts, 2006, Cancer Chemotherapy and Pharmacology.

Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.

J. Sloan, R. Diasio, R. Goldberg, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer.

A. Bartley, A. Adjei, R. Go, 2018, Lung cancer.

Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer

S. Mandrekar, N. Saijo, D. Gandara, 2015 .

ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.

H. Groen, G. Scagliotti, N. Hanna, 2022, European journal of cancer.

Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents

M. Meyerson, P. Jänne, Kwok-Kin Wong, 2006, Clinical Cancer Research.

Efforts in Lung Cancer : Focus on Early-Stage Non – Small-Cell Lung Cancer comprehensive review

H. Choy, H. Wakelee, N. Saijo, 2011 .

Management of Multifocal Lung Cancer: Results of a Survey

A. Mansfield, D. Midthun, R. Marks, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II Evaluation of Desipramine for the Treatment of Hot Flashes.

T. Rummans, T. Shanafelt, J. Sloan, 2007, Supportive cancer therapy.

A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies

R. Kurzrock, A. Naing, D. Hong, 2013, Investigational New Drugs.

Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey

E. Felip, S. Choo, J. Haanen, 2021, ESMO Open.

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

Ping Yang, A. Adjei, S. Schild, 2008, Mayo Clinic proceedings.

Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC).

H. Wakelee, D. Gandara, J. Schiller, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Unmet Needs in Oncology Clinical Research and Treatment in Africa: Focus on Ghana

L. Newman, L. Roberts, B. Awuah, 2022, The oncologist.

Small cell lung cancer.

A. Adjei, G. Dy, Alex A Adjei, 2008, Mayo Clinic proceedings.

Smoking Behavior in Patients with Early Stage NSCLC: A Report from ECOG-ACRIN 1505 Trial.

H. Wakelee, D. Gandara, S. Ramalingam, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Novel Designs and End Points for Phase II Clinical Trials

M. Christian, A. Adjei, P. Ivy, 2009, Clinical Cancer Research.

Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data

S. Mandrekar, T. Gilmer, K. Flatten, 2008, Clinical Cancer Research.

Treating cancer by blocking cell signals.

M. Hidalgo, A. Adjei, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.

Sean S. Park, Y. Li, A. Mansfield, 2018, JCI insight.

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma

A. Adjei, M. Levin, R. Amaravadi, 2015, Molecular Cancer Therapeutics.

A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies

G. Nicholas, A. Gupta, L. Chow, 2013, Cancer Chemotherapy and Pharmacology.

Report from the ASCO Virtual Congress, May 29th – 31st 2020

A. Adjei, F. Marinis, 2020, memo - Magazine of European Medical Oncology.

Phase II study of perioperative chemotherapy with cisplatin (C) and pemetrexed (P) in non-small cell lung cancer (NSCLC).

A. Adjei, T. Demmy, S. Yendamuri, 2012 .

Current guidelines for the management of small cell lung cancer.

R. Marks, A. Adjei, J. Bonner, 1999, Mayo Clinic proceedings.

A Phase I Trial of the Novel Farnesyl Protein Transferase Inhibitor, BMS-214662, in Combination with Paclitaxel and Carboplatin in Patients with Advanced Cancer

S. Mandrekar, H. Pitot, C. Erlichman, 2005, Clinical Cancer Research.

Advances in systemic therapy of small cell cancer of the lung

G. Daniels, A. Adjei, 2001, Expert review of anticancer therapy.

Current data with pemetrexed (Alimta) in non-small-cell lung cancer.

A. Adjei, 2003, Clinical lung cancer.

Current Data with Pemetrexed in Non-Small-Cell Lung Cancer

A. Adjei, 2003 .

Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.

D. Planchard, A. Adjei, A. Desai, 2021, Lung cancer.

Lung cancer: How much platinum-based chemotherapy is enough in NSCLC?

S. Peters, A. Adjei, 2015, Nature Reviews Clinical Oncology.

Novel Agents in the Treatment of Lung Cancer

G. Giaccone, M. Socinski, G. Scagliotti, 2004, Clinical Cancer Research.

A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.

J. Sloan, R. Marks, R. Goldberg, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.

J. Sloan, M. Goetz, A. Adjei, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Trial of Twice-Weekly 17-Allylamino-Demethoxy-Geldanamycin in Patients with Advanced Cancer

S. Mandrekar, C. Erlichman, A. Adjei, 2006, Clinical Cancer Research.

Report from the ASCO 2018 Congress, Chicago, June 1st-5th, 2018

A. Adjei, F. Marinis, 2018, memo - Magazine of European Medical Oncology.

Phase I and Pharmacologic Study of Infusional Topotecan and Carboplatin in Relapsed and Refractory Acute Leukemia

J. Sloan, D. Loegering, J. Karp, 2005, Clinical Cancer Research.

Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study.

J. Sosman, I. Puzanov, A. Santoro, 2012 .

Human 3'-phosphoadenosine 5'-phosphosulfate synthetase: radiochemical enzymatic assay, biochemical properties, and hepatic variation.

R. Weinshilboum, A. Adjei, A. Adjei, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Immune checkpoint inhibition : chemotherapy-free regimens & new PD-1 inhibitors on the horizon S 117 Early-stage lung cancer

B. Cho, A. Adjei, F. Marinis, 2020 .

A Primer of Chemotherapy

A. Adjei, 2001 .

Improved Response to nab-Paclitaxel Compared with Cremophor-Solubilized Paclitaxel is Independent of Secreted Protein Acidic and Rich in Cysteine Expression in Non-Small Cell Lung Cancer

Huanjie Shao, Haikuo Tang, B. Hylander, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points

J. Sloan, C. Erlichman, S. Kaufmann, 2005, Clinical Cancer Research.

A Proposed System Toward Standardizing Surgery-based Treatments for Malignant Pleural Mesothelioma, From the Joint NCI-IASLC-MARF Taskforce.

D. Sugarbaker, F. Hirsch, H. Pass, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical studies of pemetrexed and gemcitabine combinations.

A. Adjei, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

The Role of Chemotherapy in the Management of Mesothelioma

A. Adjei, J. Molina, 2006 .

A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors

J. Sloan, R. Goldberg, S. Alberts, 2005, Cancer Chemotherapy and Pharmacology.

Pharmacology and mechanism of action of pemetrexed.

A. Adjei, 2004, Clinical lung cancer.

Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies

J. Jett, R. Marks, Shaji K. Kumar, 2013, Investigational New Drugs.

A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignancies

S. Mandrekar, S. Alberts, H. Pitot, 2006, Cancer Chemotherapy and Pharmacology.

Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.

E. Felip, D. Planchard, L. Paz-Ares, 2016 .

Predicting Clinical Outcomes Using Proteomics in Non-Small Cell Lung Cancer-The Past, Present, and Future.

A. Adjei, R. Soo, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Population Pharmacokinetics of Z‐Endoxifen in Patients With Advanced Solid Tumors

Thomas R Larson, M. Goetz, A. Adjei, 2022, Journal of clinical pharmacology.

577 POSTER Selective MEK Inhibitor RDEA119 exhibits efficacy in orthotopic hepatoma models and cytostatic potential in multiple cell based models of cancer

R. Hamatake, A. Adjei, J. Miner, 2008 .

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis

A. Mansfield, Jia Wei, Baorui Liu, 2022, Frontiers in Oncology.

Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer.

A. Argiris, A. Adjei, J. Murren, 1999, Seminars in oncology.

E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC--Outcomes based on chemotherapy subsets.

H. Wakelee, D. Gandara, S. Ramalingam, 2016 .

Report from the ESMO 2019 Congress, Barcelona, September 27th – October 1st 2019

A. Adjei, F. Marinis, 2019, memo - Magazine of European Medical Oncology.

Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer.

A. Adjei, Hao Xie, 2017, Translational lung cancer research.

Anti-PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.

A. Adjei, T. Reungwetwattana, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent

A. Adjei, 2004, Clinical Cancer Research.

Toward High-Precision Genomic Biomarkers: The Importance of Context.

D. Tan, A. Adjei, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.

M. A. Mahr, Minetta C. Liu, D. Visscher, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

R. Ferris, P. Moore, V. Ganju, 2022, Journal for ImmunoTherapy of Cancer.

Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.

A. Adjei, Yujie Zhao, Alex A Adjei, 2015, The oncologist.

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.

L. Grochow, D. Noe, S. Khor, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies

A. Jimeno, E. Lam, M. Opyrchal, 2022, Cancer Chemotherapy and Pharmacology.

The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.

A. Adjei, J. Molina, 2003, Clinical lung cancer.

Pemetrexed (Alimta®): a novel multitargeted antifolate agent

A. Adjei, 2003, Expert review of anticancer therapy.

Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors.

A. Adjei, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy.

D. Prasad, Prasanna Kumar, A. Adjei, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers

A. Jimeno, E. Lam, Mojun Zhu, 2021, Cancer Chemotherapy and Pharmacology.

The Raf kinase Inhibitor BAY 43-9006 accelerates Mcl-1 degradation and regulates pro-apoptotic function

S. Kaufmann, A. Adjei, Chunrong Yu, 2005 .

Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events

Austin Miller, W. Ma, A. Adjei, 2017, Cancers.

Phase II Trial of Oral Topotecan and Intravenous Carboplatin With G-CSF Support in Previously Untreated Patients With Extensive Stage Small Cell Lung Cancer: A North Central Cancer Treatment Group Study

E. Perez, J. Jett, S. Hillman, 2010, American journal of clinical oncology.

A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM).

H. Wakelee, B. Sikic, A. Adjei, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

L. Grochow, R. Donehower, S. Kaufmann, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclinical and clinical studies with combinations of pemetrexed and gemcitabine.

A. Adjei, 2002, Seminars in oncology.

Current status of pyrazoloacridine as an anticancer agent

A. Adjei, 2004, Investigational new drugs.

Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.

S. Kaufmann, P. Svingen, A. Adjei, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients

R. Kumar, S. Mandrekar, N. Foster, 2020, Journal of cachexia, sarcopenia and muscle.

Characterization of a Human Carcinoma Cell Line Selected for Resistance to the Farnesyl Transferase Inhibitor 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336)

S. Kaufmann, A. Adjei, L. Bruzek, 2005, Molecular Pharmacology.

A phase II study of a combination of pemetrexed (Pem) and gemcitabine (Gem) in patients with metastatic breast cancer (MBC): An NCCTG study.

E. Perez, J. Ingle, J. Kugler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting PIM2 by JP11646 results in significant antitumor effects in solid tumors

M. Opyrchal, A. Adjei, I. Gelman, 2022, International journal of oncology.

A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors

Mojun Zhu, A. Tan, A. Adjei, 2020, Investigational New Drugs.

Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors.

J. Jett, J. Sloan, R. Goldberg, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy

A. Adjei, 2001 .

Dehydroepiandrosterone for the treatment of hot flashes: a pilot study.

T. Rummans, T. Shanafelt, P. Carpenter, 2006, Supportive cancer therapy.

Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships.

A. Bezjak, S. Mandrekar, D. Camidge, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer 1

S. Larson, A. Scott, J. Ingle, 2003 .

The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours

A. Adjei, L. Porrata, 2001, British Journal of Cancer.

' Phase J, study of the matrix metalloproteinase inhibitor, BAY 12-956^

J. Sloan, R. Goldberg, S. Alberts, 2001 .

A Phase II NCCTG Study of Irinotecan and Docetaxel in Previously Treated Patients with Non-Small Cell Lung Cancer

J. Jett, S. Hillman, K. Rowland, 2006, Cancer investigation.

Report from the ASCO 2019 Congress, Chicago, May 31st – June 4th 2019

A. Adjei, F. Marinis, 2019, memo - Magazine of European Medical Oncology.

Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer.

D. V. Von Hoff, G. Weiss, M. Jeffers, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors

J. Berlin, A. Jimeno, P. LoRusso, 2011, Clinical Cancer Research.

Does the Lung Cancer Field Need Another Third-Generation EGFR Tyrosine Kinase Inhibitor?

A. Adjei, Fen Wang, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Protection against fludarabine neurotoxicity in leukemic mice by the nucleoside transport inhibitor nitrobenzylthioinosine

A. Adjei, L. Dagnino, A. Paterson, 2004, Cancer Chemotherapy and Pharmacology.

Novel Anticancer Agents

J. Buolamwini, A. Adjei, 2006 .

Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin.

A. Adjei, R. Go, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A clinician's guide to bioinformatics for next-generation sequencing.

A. Oberg, N. Larson, Liguo Wang, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

New Pulmonary Infiltrates Observed on Computed Tomography-Based Image Guidance for Radiotherapy Warrant Diagnostic Workup for Coronavirus Disease 2019

G. Warren, A. Adjei, C. Billiet, 2021, Journal of Thoracic Oncology.

Report from the virtual World Conference on Lung Cancer, 8th –14th September 2021, and the virtual ESMO Congress, 16th –21st September, 2021

A. Adjei, 2021, memo - Magazine of European Medical Oncology.

Expansion of treatments and insights in the early-stage disease setting S 146 Innovative and established agents across a range of targets S 152 Immunotherapy : boosting efficacy and overcoming resistance

A. Adjei, 2021 .

Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy

A. Adjei, Bret B Friday, Alex A Adjei, 2008, Clinical Cancer Research.

Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine.

T. Rummans, T. Shanafelt, J. Sloan, 2005, Journal of palliative medicine.

Phase II Trial of KW2189 in Patients With Advanced Malignant Melanoma

S. Alberts, V. Suman, A. Adjei, 2002, American journal of clinical oncology.

Phase I dose escalation study of the PKC&igr; inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer

A. Mansfield, C. Erlichman, A. Fields, 2013, Anti-cancer drugs.

A Call for Rapid Submission of Data for Aggregate Review: Can Daily Radiotherapy Imaging Be Used as a Potential Screen for Coronavirus Disease 2019?

G. Warren, A. Adjei, 2020, Journal of Thoracic Oncology.

Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003.

S. Thibodeau, J. Jett, R. Marks, 2005, Chest.

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.

S. Peters, A. Adjei, S. Zimmermann, 2014, Cancer treatment reviews.

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.

D. Loegering, K. Flatten, N. T. Dai, 2009, Blood.

Farnesyl transferase inhibitors as anticancer agents.

A. Adjei, G. Dy, P. Haluska, 2002, European journal of cancer.

Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors

A. Adjei, P. Haluska, T. Yap, 2007, Clinical Cancer Research.

Nucleoside Transport Inhibition In Vitro and In Vivo

A. Adjei, A. Paterson, C. Ng, 1987 .

Targeting Apoptosis Pathways in Cancer Therapy

A. Adjei, I. Ghobrial, T. Witzig, 2005, CA: a cancer journal for clinicians.

Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).

S. Hillman, R. Marks, J. Kugler, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).

E. Perez, J. Jett, S. Mandrekar, 2008, Lung cancer.

Complementary and alternative medicine use by patients enrolled onto phase I clinical trials.

J. Sloan, S. Mandrekar, A. Adjei, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Culture media composition influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancers

Hu Li, M. Toruner, A. Oberg, 2022, JCI insight.

FGFR Signaling as a Target for Lung Cancer Therapy

A. Adjei, A. Desai, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.

G. Ahmann, R. Fonseca, B. Djulbegovic, 2004 .

A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.

W. R. Bishop, J. Sloan, J. Sloan, 2000, Cancer research.

Ras signaling pathway proteins as therapeutic targets.

A. Adjei, A A Adjei, 2001, Current pharmaceutical design.

Understanding, recognizing, and managing toxicities of targeted anticancer therapies

A. Adjei, G. Dy, Alex A Adjei, 2013, CA: a cancer journal for clinicians.

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

W. Franklin, L. Chow, S. Leong, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarker Discovery and Validation: Statistical Considerations.

A. Oberg, S. Michiels, Y. Shyr, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Current status of clinical trials of farnesyltransferase inhibitors

J. Karp, S. Kaufmann, J. Lancet, 2001, Current opinion in oncology.

Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.

C. Erlichman, S. Kaufmann, A. Adjei, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

MET: a promising anticancer therapeutic target

S. Peters, A. Adjei, Solange Peters, 2012, Nature Reviews Clinical Oncology.

Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination.

V. Lowe, M. Borad, T. Smyrk, 2020, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.

J. Sarkaria, P. Atadja, D. Wigle, 2008, Neuro-oncology.

Strategies for improving outcomes in NSCLC: a look to the future.

A. Marchetti, F. Cappuzzo, D. de Ruysscher, 2013, Lung cancer.

The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy.

A. Adjei, 2005, Clinical lung cancer.

Lung cancer and metastasis: new opportunities and challenges

A. Adjei, Xiangdong Wang, 2015, Cancer and Metastasis Reviews.

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

K. Rosenzweig, M. Zauderer, V. Rusch, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lung cancer-celebrating progress and acknowledging challenges.

A. Adjei, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations.

G. Scagliotti, R. Herbst, S. Gettinger, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pathologic considerations and standardization in mesothelioma clinical trials.

A. Nicholson, F. Galateau-Sallé, D. Gomez, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Current Diagnosis and Management of Small-Cell Lung Cancer.

A. Mansfield, Shuhang Wang, A. Adjei, 2019, Mayo Clinic proceedings.

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors

R. Neuwirth, J. Sosman, A. Ribas, 2016, Investigational New Drugs.

Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor

A. Adjei, P. Haluska, A. Gualberto, 2007, Clinical Cancer Research.

Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.

A. Adjei, K. Miller-Moslin, Jillian L. Brechbiel, 2014, Cancer treatment reviews.

KRAS: From undruggable to a druggable Cancer Target.

A. Adjei, D. Uprety, 2020, Cancer treatment reviews.

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

S. Peters, A. Adjei, T. Nguyen-Ngoc, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.

R. Marks, E. Vokes, C. Erlichman, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

"Targeted" therapies for non-small cell lung cancer.

A. Adjei, 2002, Clinical lung cancer.

A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors

B. Sikic, P. LoRusso, W. Ma, 2016, Investigational New Drugs.

eview trategies for improving outcomes in NSCLC : A look to the future

D. Fennell, A. Adjei, olf Stahela, 2013 .

Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups

Y. Asmann, P. L. Bergsagel, A. Mansfield, 2021, npj Precision Oncology.

Inhibitors of the ras oncogene as therapeutic targets.

A. Adjei, I. Ghobrial, 2002, Hematology/oncology clinics of North America.

Comparison of potential markers of farnesyltransferase inhibition.

C. Erlichman, S. Kaufmann, P. Svingen, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

New strategies to develop new medications for lung cancer and metastasis

A. Adjei, Yujie Zhao, 2015, Cancer and Metastasis Reviews.

K-ras as a target for cancer therapy.

A. Adjei, Bret B Friday, Alex A Adjei, 2005, Biochimica et biophysica acta.

REVIEW Blocking Oncogenic Ras Signaling for Cancer Therapy

A. Adjei, 2001 .

Novel Combinations Based on Epidermal Growth Factor Receptor Inhibition

A. Adjei, 2006, Clinical Cancer Research.

Survival of Black and White Patients With Stage IV Small Cell Lung Cancer

A. Adjei, Y. Lou, R. Manochakian, 2021, Frontiers in Oncology.

A Proposed System Toward Standardizing Surgery-based Treatments for Malignant Pleural Mesothelioma, From the Joint NCI-IASLC-MARF Taskforce.

V. Rusch, D. Sugarbaker, R. Bueno, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Ras/Raf/MAPK pathway.

A. Adjei, J. Molina, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Sorafenib, a multikinase inhibitor, is effective in vitro against non‐hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin

S. Vincent Rajkumar, Shaji K. Kumar, A. Adjei, 2012, American journal of hematology.

Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy

C. Reynolds, M. Goetz, J. Ingle, 2008, Molecular Cancer Therapeutics.

Gemcitabine and pemetrexed disodium combinations in vitro and in vivo.

A. Adjei, 2001, Lung cancer.

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours

C. Rudin, A. Jimeno, N. Senzer, 2013, British Journal of Cancer.

Protein farnesyl transferase as a target for the development of anticancer drugs

A. Adjei, 2000 .

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.

H. Groen, J. Ware, K. Morrissey, 2017, European Journal of Cancer.

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer

P. LoRusso, Z. Wainberg, C. Britten, 2014, Investigational New Drugs.

A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC).

J. Ware, J. Soria, R. Brachmann, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Emerging therapeutic targets in non-small cell lung cancer.

A. Adjei, G. Dy, 2009, Proceedings of the American Thoracic Society.

Management of small cell cancer of the lung.

A. Adjei, 2000, Current opinion in pulmonary medicine.

Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.

J. Sloan, R. Goldberg, S. Alberts, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis

David Loegering, Sun-Hee Lee, Chunrong Yu, 2007, Journal of Biological Chemistry.

BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.

Chunrong Yu, S. Thibodeau, Liang Wang, 2008, Cancer research.

Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways

V. Golubovskaya, W. Cance, Huanjie Shao, 2016, British Journal of Cancer.

Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens

K. White, A. Mansfield, N. Beaubier, 2020, JAMA network open.

Cooperative group research endeavors in small-cell lung cancer: current and future directions.

H. Choy, N. Saijo, D. Gandara, 2009, Clinical lung cancer.

Systemic cancer therapy: Evolution over the last 60 years

A. Adjei, G. Dy, 2008, Cancer.

Evaluation of Lapatinib andTopotecan CombinationTherapy : Tissue Culture , Murine Xenograft , and Phase I ClinicalTrial Data

T. Gilmer, K. Flatten, C. Erlichman, 2008 .

All That Glitters Is Not Gold: The Story of Rovalpituzumab Tesirine in SCLC.

A. Adjei, J. Remon, D. Uprety, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer

J. Neal, H. Wakelee, J. Riess, 2013, British Journal of Cancer.

Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.

M. Hidalgo, C. Erlichman, A. Adjei, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abrogation of MAPK and Akt Signaling by AEE788 Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis through Reactive Oxygen Species Generation

P. Atadja, L. Roberts, A. Adjei, 2007, Clinical Cancer Research.

Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.

A. Adjei, B. Schwartz, E. Garmey, 2011, The oncologist.

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors

Chun-Fang Xu, S. Novello, J. Bendell, 2013, Investigational New Drugs.

Impact of Pretreatment Factors on Adverse Events: A Pooled Analysis of North Central Cancer Treatment Group Advanced Stage Non-small Cell Lung Cancer Trials

J. Jett, B. Bot, S. Mandrekar, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Novel pharmacological agents in clinical development for solid tumours

A. Adjei, G. Dy, P. Haluska, 2001, Expert opinion on investigational drugs.

ALK inhibitors in the treatment of advanced NSCLC.

C. Gridelli, S. Peters, F. Ciardiello, 2014, Cancer treatment reviews.

Metaplastic breast cancer: prognosis and response to systemic therapy.

J. Ingle, A. Adjei, V. Suman, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

The clinical development of MEK inhibitors

A. Adjei, Yujie Zhao, 2014, Nature Reviews Clinical Oncology.

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.

P. Greenberg, Y. Park, J. Karp, 2007, Blood.

Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer.

C. Obasaju, J. Jett, S. Mandrekar, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer.

S. Rajkumar, A. Adjei, 1998, Cancer treatment reviews.

In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs

N. Sharma, A. Adjei, 2011, Therapeutic advances in medical oncology.

Targeting oncogenic drivers.

A. Adjei, Yujie Zhao, 2014, Progress in tumor research.

A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies

H. Wakelee, B. Sikic, A. Adjei, 2018, Cancer Chemotherapy and Pharmacology.

A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer

F. Hirsch, W. Franklin, M. Varella‐Garcia, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

cytotoxicity in human leukemia cells Involvement of reactive oxygen species in adaphostin-induced

E. Sausville, D. Loegering, J. Karp, 2013 .

Patient Selection for Rational Development of Novel Anticancer Agents

A. Adjei, G. Dy, 2008 .

Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells.

E. Sausville, D. Loegering, J. Karp, 2003, Blood.

A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors

M. Hidalgo, A. Tolcher, J. Soria, 2016, Clinical Cancer Research.

A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group Study N0528

S. Mandrekar, A. Adjei, A. Adjei, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Correlation Between Polymorphisms of the Reduced Folate Carrier Gene (SLC19A1) and Survival After Pemetrexed-Based Therapy in Non-small Cell Lung Cancer: A North Central Cancer Treatment Group-Based Exploratory Study

S. Mandrekar, A. Adjei, A. Adjei, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

"I think it's been met with a shrug:" Oncologists' views toward and experiences with Right-to-Try.

J. Buckner, J. Tilburt, A. Adjei, 2020, Journal of the National Cancer Institute.

Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years.

A. Mansfield, A. Adjei, C. Haddox, 2018, Journal of oncology practice.

Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents

G. Yancopoulos, G. Thurston, A. Adjei, 2006, Cancer and Metastasis Reviews.

A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors

M. Goetz, S. Kaufmann, A. Adjei, 2018, Investigational New Drugs.

Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies

Erin L. Schenk, B. Costello, L. Doyle, 2021, Investigational New Drugs.

A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine‐based chemotherapy in patients with advanced solid tumors

W. Bshara, M. Opyrchal, W. Ma, 2021, International journal of cancer.

Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?

A. Mansfield, A. Adjei, Y. Lou, 2019, The oncologist.

A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma

D. Gandara, C. Erlichman, A. Adjei, 2019, Investigational New Drugs.

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

A. Jimeno, W. Ma, A. Adjei, 2012, Clinical Cancer Research.

Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells

A. Oberg, F. Sinicrope, D. Loegering, 2014, Haematologica.

A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients

W. Ma, A. Adjei, G. Dy, 2019, American journal of clinical oncology.

Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic

G. Scagliotti, E. Smit, A. Dingemans, 2020, Journal of Thoracic Oncology.

Treatment guidance for lung cancer patients during the COVID-19 pandemic

G. Scagliotti, E. Smit, A. Dingemans, 2020, Journal of Thoracic Oncology.

Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations

S. Mandrekar, A. Adjei, Jack J. Lee, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors

A. Adjei, D. Satele, J. Molina, 2018, Investigational New Drugs.

Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy

D. Ettinger, F. Cappuzzo, E. Smit, 2016, ESMO Open.

A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.

A. Scott, J. Ingle, A. Papenfuss, 2007, Cancer immunity.

Antiangiogenic Therapy for Lung Cancer: Small-Molecule Inhibitors

A. Adjei, N. Ramnath, 2007 .

A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.

R. Marks, N. Foster, A. Adjei, 2014, Lung cancer.

Novel Anticancer Agents in Clinical Development

A. Adjei, E. Rowinsky, 2003, Cancer biology & therapy.

Receptor tyrosine kinase inhibitors.

A. Adjei, P. Haluska, 2001, Current opinion in investigational drugs.

A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors

W. Ma, A. Adjei, G. Dy, 2014, Investigational New Drugs.

A phase I study of birinapant (TL32711) combined with multiple chemotherapies evaluating tolerability and clinical activity for solid tumor patients.

N. Senzer, P. LoRusso, K. Papadopoulos, 2013 .

Phase II Study of Perioperative Chemotherapy with Cisplatin and Pemetrexed in Non–Small-Cell Lung Cancer

A. Adjei, T. Demmy, S. Yendamuri, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

2006 Highlights From: The European Society for Medical Oncology Congress Istanbul, Turkey; Sept. 29-Oct. 3, 2006 International Association for the Study of Lung Cancer Early Invasive Lung Cancer Workshop Turin, Italy; Sept. 25–26, 2006

A. Adjei, P. Lara, A. Ranganathan, 2006 .

A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group (NCCTG)-N0321

S. Mandrekar, N. Foster, M. Aubry, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

385 A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results

J. Berlin, A. Adjei, P. Swiecicki, 2020 .

Prognostic factors differ by tumor stage for small cell lung cancer

J. Jett, S. Mandrekar, R. Marks, 2009, Cancer.

A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors.

J. Sloan, R. Goldberg, H. Pitot, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer.

J. Jett, S. Hillman, D. Northfelt, 2005, International journal of radiation oncology, biology, physics.

Long‐Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance)

J. Jett, S. Hillman, A. Tan, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Sulfatase 2 up‐regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma

S. Thorgeirsson, T. Han, Ju-Seog Lee, 2008, Hepatology.

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.

W. R. Bishop, R. Sullivan, K. Flaherty, 2018, JCI insight.

Novel targets for lung cancer therapy: part I.

A. Adjei, G. Dy, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract A25: Phase 1 PK/PD analysis of the Smac-mimetic TL32711 demonstrates potent and sustained cIAP1 suppression in patient PBMCs and tumor biopsies.

A. Tolcher, P. LoRusso, K. Papadopoulos, 2011 .

Lung cancer lymph node micrometastasis detection using real-time polymerase chain reaction: correlation with vascular endothelial growth factor expression.

C. Morrison, A. Hutson, R. Cheney, 2013, The Journal of thoracic and cardiovascular surgery.

Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-small Cell Lung Cancer

J. Sloan, S. Mandrekar, J. Krook, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.

J. Sloan, R. Goldberg, S. Alberts, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

D. V. Von Hoff, G. Weiss, M. Jeffers, 2013, Clinical Cancer Research.

Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review.

S. Mandrekar, S. Hillman, U. Gatzemeier, 2011, Clinical lung cancer.

Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.

L. Grochow, R. Donehower, S. Kaufmann, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

North Central Cancer Treatment Group--achievements and perspectives.

E. Perez, J. Buckner, D. Sargent, 2008, Seminars in oncology.

Farnesyltransferase inhibitors.

S. Sebti, A. Adjei, 2004, Seminars in oncology.

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations

A. Bardelli, L. Trusolino, A. Bertotti, 2016, Science Translational Medicine.

A prognostic model for advanced stage nonsmall cell lung cancer

J. Jett, S. Mandrekar, S. Hillman, 2006, Cancer.

Cancer symposium for the practitioner: introduction to solid tumors.

S. Rajkumar, A. Tefferi, A. Adjei, 2007, Mayo Clinic proceedings.

A Phase I and Pharmacologic Study of Pyrazoloacridine and Cisplatin in Patients with Advanced Cancer

D. Noe, R. Donehower, A. Adjei, 2003, Investigational New Drugs.

A Phase I and Pharmacologic Study of Pyrazoloacridine (NSC 366140) and Carboplatin in Patients with Advanced Cancer

J. Sloan, R. Goldberg, S. Alberts, 2002, Investigational New Drugs.

A phase II study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

P. Greenberg, Y. Park, J. Karp, 2006 .

Outstanding Issues with Umbrella and Basket Studies.

A. Adjei, K. Parikh, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Introduction to a cancer symposium for the practitioner.

S. Rajkumar, A. Tefferi, A. Adjei, 2005, Mayo Clinic proceedings.

Human aromatase: gene resequencing and functional genomics.

Eric D Wieben, Richard M Weinshilboum, Liewei Wang, 2005, Cancer research.

Evaluation of Glutathione Metabolic Genes on Outcomes in Advanced Non-small Cell Lung Cancer Patients after Initial Treatment with Platinum-Based Chemotherapy: An NCCTG-97-24-51 Based Study

Zhifu Sun, Sumithra J Mandrekar, Ping Yang, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Signal transduction pathway targets for anticancer drug discovery.

A. Adjei, 2000, Current pharmaceutical design.

Farnesyltransferase Inhibitors in Breast Cancer Therapy

A. Adjei, G. Dy, 2002, Cancer investigation.

Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.

S. Mandrekar, D. Gandara, A. Adjei, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line Treatment of Metastatic Lung Cancer—New Developments

A. Adjei, G. Dy, 2008 .

Pemetrexed in the treatment of selected solid tumors.

A. Adjei, 2002, Seminars in oncology.

Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer.

H. Choy, H. Wakelee, N. Saijo, 2008, Clinical lung cancer.

Oncologists’ reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center

J. Buckner, J. Tilburt, A. Adjei, 2021, PloS one.

Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution.

J. Jett, R. Marks, A. Adjei, 2005, Lung cancer.

Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies

U. Dafni, J. Tabernero, S. Choo, 2021, ESMO open.

Representation of minorities in oncology clinical trials: Review of the past 14 years.

A. Mansfield, A. Adjei, Yucai Wang, 2017 .

A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer

H. Hurwitz, S. Kaufmann, A. Adjei, 2011, Cancer investigation.

Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials

D. Sargent, S. George, E. Vokes, 2017, The oncologist.

A front‐line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer

S. Mandrekar, S. Hillman, S. Nair, 2010, Cancer.

Impact of disease progression date determination on progression‐free survival estimates in advanced lung cancer

S. Mandrekar, S. Hillman, D. Gandara, 2012, Cancer.

Trends in Prices of Drugs Used to Treat Metastatic Non–Small Cell Lung Cancer in the US From 2015 to 2020

N. Shah, A. Adjei, J. Orme, 2022, JAMA Network Open.

Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer

A. Adjei, D. Uprety, Joel Rivera-Concepción, 2022, Cancer research and treatment.

A randomized double-blind phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: NCCTG (Alliance) N0923 Study.

Erin L. Schenk, J. Nieva, S. Mandrekar, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Results of combined‐modality therapy for limited‐stage small cell lung carcinoma in the elderly

J. Jett, S. Mandrekar, J. Krook, 2005, Cancer.

PD-080 A pooled analysis of 11 NCCTG advanced stage non-small cell lung cancer (NSCLC) trials reveals the importance of baseline blood counts on clinical outcomes

J. Jett, S. Mandrekar, S. Hillman, 2005 .

A Call to Arms: Reducing Disparities in Lung Cancer Care Worldwide.

A. Adjei, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lung cancer and metastasis: new opportunities and challenges

A. Adjei, Xiangdong Wang, 2015, Cancer and Metastasis Reviews.

A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study.

E. Perez, J. Ingle, J. Kugler, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I Clinical Trials with Anticancer Agents

S. Leong, A. Adjei, W. Messersmith, 2011 .

Prospective observational comparison of clinical outcomes between african-american and caucasian patients receiving second-line treatment with pemetrexed for advanced non-small-cell lung cancer.

C. Obasaju, E. Stepanski, A. Adjei, 2013, Clinical lung cancer.

Abstract CT139: Ceritinib (Cer) in combination with gemcitabine (Gem)-based chemotherapy in patients (pts) with advanced solid tumors, a phase I study

M. Opyrchal, W. Ma, A. Adjei, 2020 .

Report from the WCLC 2017 Congress, Yokohama, 15th–18th October, 2017

A. Adjei, F. Marinis, 2017, memo - Magazine of European Medical Oncology.

5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study.

D. Midthun, Yuh-Min Chen, Ping Yang, 2019, The Lancet. Oncology.

Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress.

H. Choy, H. Wakelee, B. Loo, 2009, Clinical lung cancer.

Phase IDose Escalation Study of theAnti ^ Insulin-Like Growth Factor-IReceptor Monoclonal Antibody CP-751 , 871 in Patients with Refractory SolidTumors

A. Adjei, P. Haluska, T. Yap, 2007 .

SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.

Chunrong Yu, T. Han, C. Moser, 2006, Gastroenterology.

Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012.

H. Cohen, J. Manola, D. Sargent, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

D7-07: A phase II NCCTG “Window of Opportunity Front-line” study of the mTOR Inhibitor, CCI-779 (Temsirolimus) given as a single agent in patients with advanced NSCLC

J. Jett, S. Mandrekar, R. Marks, 2007 .

T-Cell Engagers in Solid Cancers—Current Landscape and Future Directions

W. Ma, A. Adjei, P. Caimi, 2023, Cancers.

Tackling the High Cost of Oncology Drugs.

A. Adjei, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance).

S. Mandrekar, A. Tan, A. Adjei, 2019, The oncologist.

Novel agents in the treatment of lung cancer: conference summary statement.

G. Giaccone, M. Socinski, G. Scagliotti, 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

What is the right dose? The elusive optimal biologic dose in phase I clinical trials.

A. Adjei, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models

B. Hylander, E. Repasky, A. Adjei, 2013, British Journal of Cancer.

Survival trends among non‐small‐cell lung cancer patients over a decade: impact of initial therapy at academic centers

Margaret M. Johnson, D. Hodge, RobertI Miller, 2018, Cancer medicine.

Systemic Chemotherapy in Patients With Renal Failure

A. Adjei, L. Bekele, Marieberta Vidal Vazquez, 2001, American journal of clinical oncology.

The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3–dependent Wnt activation

T. Han, S. Sanderson, C. Moser, 2010, Hepatology.

Safety, pharmacology, and preliminary clinical activity of MM-151: An oligocolnal anti-EGFR theraputic in patients with cetuximab-resistant CRC and other refractory solid tumors.

M. Beeram, A. Adjei, B. Wolf, 2015 .

Identification and characterization of genetic variation in the folylpolyglutamate synthase gene.

A. Adjei, A. Adjei, G. Dy, 2007, Cancer research.

Advances in chemotherapy of non-small cell lung cancer.

J. Jett, A. Adjei, J. Molina, 2006, Chest.

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

J. Sosman, I. Puzanov, A. Santoro, 2014, Investigational New Drugs.

Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia

D. Steensma, R. Mesa, D. Loegering, 2011, Haematologica.

Congress Report ASCO 2017

A. Adjei, F. Marinis, 2017, memo - Magazine of European Medical Oncology.

Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.

R. Neuwirth, J. Sosman, A. Ribas, 2013 .

Abstract 4716: A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors

B. Sikic, P. LoRusso, W. Ma, 2011 .

Report from the WCLC 2020 virtual Congress, January 28th–31th, 2021

A. Adjei, F. Marinis, 2021, memo - Magazine of European Medical Oncology.

151 Allosteric MEK inhibitor BAY 86-9766 (RDEA119) shows anti-tumor efficacy in mono-and combination therapy in preclinical models of hepatocellular carcinoma and pancreatic cancer

Robert Schmieder, A. Adjei, K. Ziegelbauer, 2010 .

A phase Ib trial of CB-839 (telaglenastat) in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma (NCT03528642).

J. Port, A. Chakravarti, A. Adjei, 2019, Journal of Clinical Oncology.

Influence of Sociodemographic Factors on Treatment Decisions in Non-Small-Cell Lung Cancer.

A. Mansfield, A. Adjei, Y. Lou, 2020, Clinical lung cancer.

A phase I dose-escalation and pharmacokinetic (PK) study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies

H. Wakelee, B. Sikic, A. Adjei, 2005 .

A phase I trial of MTA and gemcitabine in patients with locally advanced or metastatic cancer.

C. Erlichman, A. Adjei, 1999, Seminars in oncology.

Cerebral nocardiosis mimicking multiple brain metastases in a patient with locally advanced non-small-cell lung cancer.

R. Meuli, S. Peters, A. Adjei, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II clinical activity and tolerability of the SMAC-mimetic birinapant (TL32711) plus irinotecan in irinotecan-relapsed/refractory metastatic colorectal cancer.

N. Senzer, P. LoRusso, K. Papadopoulos, 2013 .

Comparison of Continuous versus Categorical Tumor Measurement–Based Metrics to Predict Overall Survival in Cancer Treatment Trials

Sumithra J. Mandrekar, Henry C. Pitot, Daniel J. Sargent, 2011, Clinical Cancer Research.

Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

S. Mandrekar, S. Hillman, R. Marks, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Multitrial evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in previously untreated extensive-stage small cell lung cancer (ES-SCLC): An Alliance-led analysis.

S. Mandrekar, D. Gandara, K. Ding, 2013 .

Phase 1b study of the oral gemcitabine ‘Pro-drug’ LY2334737 in combination with capecitabine in patients with advanced solid tumors

J. Bendell, J. Infante, W. Ma, 2015, Investigational New Drugs.

NCCTG N0821 (Alliance): A Phase II First-Line Study of Pemetrexed, Carboplatin, and Bevacizumab in Elderly Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer With Good Performance Status

S. Mandrekar, M. Aubry, A. Adjei, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Novel anticancer drug protocols

J. Buolamwini, A. Adjei, 2003 .

Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study.

J. Sosman, I. Puzanov, W. Ma, 2012 .

Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report.

A. Mansfield, R. Marks, A. Adjei, 2023, Cancer treatment and research communications.

A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study.

S. Mandrekar, N. Foster, M. Aubry, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary results of ENCORE 601, a phase 1b/2, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC).

George A. Dominguez, P. Jänne, S. Ramalingam, 2016 .

2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.

C. Dooms, A. Marchetti, K. Syrigos, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.

C. Dooms, A. Marchetti, L. Bubendorf, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies.

J. Berlin, P. Philip, T. Bekaii-Saab, 2018 .

2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.

S Senan, C. Dooms, A. Marchetti, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Guidelines for Statistical Reporting in Medical Journals.

S. Mandrekar, K. Ballman, A. Adjei, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Farnesyltransferase inhibitors.

A. Adjei, 2003, Cancer chemotherapy and biological response modifiers.

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia : a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib ( R 115777 , Zarnestra ) combined with etoposide

D. Loegering, K. Flatten, N. T. Dai, 2008 .

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.

P Baas, C. Dooms, A. Marchetti, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract C191: Preclinical investigation of the antitumor efficacy in lung cancer of Y15, a novel focal adhesion kinase inhibitor.

V. Golubovskaya, W. Cance, Huanjie Shao, 2011 .

2006 Highlights From: The Third International Association for the Study of Lung Cancer/American Society of Clinical Oncology/European Society of Medical Oncology International Conference on Molecular-Targeted Therapies in Lung Cancer Taormina, Sicily; November 2006

R. Herbst, F. Hirsch, H. Pass, 2007 .

Principles of chemotherapy

A. Adjei, G. Dy, J. A. McKnight, 2006 .

Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation

F. Janku, M. Opyrchal, A. Wicki, 2019 .

26 ORAL Phase Ib and pharmacodynamic study of the MEK inhibitor AZD6244 (ARRY-142886) in patients with advanced solid malignancies

W. Franklin, A. Adjei, R. Cohen, 2006 .

Expanding the KRASG12C Inhibitor Class: What Do We Need Next?

A. Adjei, Aurora Norman, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.

J. Sloan, J. Sloan, R. Goldberg, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pathophysiology and treatment of hot flashes. Editorial

T. Shanafelt, C. Loprinzi, R. Santen, 2002 .

Farnesyltransferase inhibitor FTI‐R115777 is well tolerat ed, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

G. Ahmann, R. Fonseca, B. Djulbegovic, 2003, Blood.

A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin

S. Mandrekar, C. Erlichman, A. Tan, 2007, Cancer Chemotherapy and Pharmacology.

D. Loegering, K. Flatten, J. Karp, 2009, Blood.

A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

M. Sherman, A. Hezel, A. El-Khoueiry, 2015, Clinical Cancer Research.

Sorafenib, a multikinase inhibitor, is effective in vitro against non‐hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin

S. Vincent Rajkumar, Shaji K. Kumar, A. Adjei, 2012, American journal of hematology.

S. Mandrekar, N. Foster, M. Aubry, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.

S. Peters, A. Adjei, S. Zimmermann, 2014, Cancer treatment reviews.

Brief Report: A Phase II “Window-of-Opportunity” Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an NCCTG Study

J. Jett, S. Mandrekar, R. Marks, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic factors differ by tumor stage for small cell lung cancer

J. Jett, S. Mandrekar, R. Marks, 2009, Cancer.

Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing.

Marshall W. Anderson, X. Hua, C. Morrison, 2012, Carcinogenesis.

Sulfatase 2 up‐regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma

S. Thorgeirsson, T. Han, Ju-Seog Lee, 2008, Hepatology.

CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.

Sean S. Park, Y. Li, A. Mansfield, 2018, JCI insight.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

A. Jimeno, W. Ma, A. Adjei, 2012, Clinical Cancer Research.

A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia.

K. Flatten, A. Adjei, I. Aldoss, 2023, Cancer medicine.

Small cell lung cancer.

A. Adjei, G. Dy, T. Sher, 2008, Mayo Clinic proceedings.

Phase I I S tudy o f t he F arnesyl T ransferase I nhibitor R 115777 in P atients W ith A dvanced N on-Small-Cell L ung C ancer

R. Marks, E. Vokes, C. Erlichman, 2003 .

A challenging case of stage IV EGFR-mutant lung cancer with histologic transformation and multiple resistance mechanisms

A. Adjei, D. Uprety, Joel Rivera-Concepción, 2024, Current Problems in Cancer: Case Reports.

Prospective observational comparison of clinical outcomes between african-american and caucasian patients receiving second-line treatment with pemetrexed for advanced non-small-cell lung cancer.

C. Obasaju, E. Stepanski, A. Adjei, 2013, Clinical lung cancer.

A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors

M. Hidalgo, A. Tolcher, J. Soria, 2016, Clinical Cancer Research.

Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer.

H. Choy, H. Wakelee, N. Saijo, 2008, Clinical lung cancer.

Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.

J. Sloan, R. Goldberg, H. Pitot, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Evaluation of Quality-of-life (QoL) in patients(pts) with advanced solid tumors as screening tool during phase 1 clinical trial recruitment- risk assessment for adverse events and subject replacement.

Austin Miller, W. Ma, A. Adjei, 2015 .

Phase 1 study of REGN1400 (anti-ErbB3) combined with erlotinib or cetuximab in patients (pts) with advanced non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck cancer (SCCHN).

I. Lowy, K. Papadopoulos, D. Rasco, 2014 .

A phase I study of MM-121 in combination with multiple anticancer therapies in patients with advanced solid tumors.

J. Soria, A. Adjei, G. Dy, 2013 .

A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM).

B. Sikic, A. Adjei, J. Reid, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer

S. Mandrekar, E. Vokes, A. Adjei, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.

J. Jett, S. Mandrekar, M. Aubry, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.